Evaluation of efficacy and safety of the Qing Dai in patients with ulcerative colitis: A muticenter, double-blind, randomized controlled trial.

Evaluation of efficacy and safety of the Qing Dai in patients with ulcerative colitis: A muticenter, double-blind, randomized controlled trial. - A muticenter, double-blind, randomized controlled trial of the Qing Dai.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019103

Enrollment

Registered

2015-10-01

Start date

2015-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

Qing Dai:s weeks, 1000mg aday rice starch

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: UC patients in mild to moderate active phase with intolerance or refractory with conventional treatments.

Exclusion criteria

Exclusion criteria: The patients with... 1. newly start or dose-up of 5-ASA within two weeks. 2. newly start or dose-up of steroids within two weeks. 3. newly start or dose-up of immunomodulators, such as azathioprine/6-methyl mercaptopurine within three months. 4. with biological products, such as Infliximab, and Adalimumab. 5. any herbal medicine containing the Qing Dai. 6. a possibility of pregnancy, during pregnancy, or lactating. 7. any mental illness that interfere to participate this trial. 8. active bacterial/fungal infections 9. history of myocardial infarction or unstable angina within three months. 10. uncontrollable hypertension 11. respiratery disease requiring a sustained oxigen administration.

Design outcomes

Primary

Measure	Time frame
Disease activity index(Lichtiger index)	—

Secondary

Measure	Time frame
Endoscopic findings, Blood test, Adverse reactions	—

Countries

Japan

Contacts

Public ContactKan Uchiyama

The Jikei University Kashiwa Hospital Division of Gastroenterology and Hepatology

uchikan@jikei.ac.jp04-7164-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026